Squarepoint Ops LLC Purchases 4,464 Shares of argenx SE (NASDAQ:ARGX)

Squarepoint Ops LLC increased its stake in argenx SE (NASDAQ:ARGX - Free Report) by 24.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,664 shares of the company's stock after acquiring an additional 4,464 shares during the quarter. Squarepoint Ops LLC's holdings in argenx were worth $13,938,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of ARGX. FMR LLC grew its position in argenx by 17.2% during the fourth quarter. FMR LLC now owns 5,618,222 shares of the company's stock valued at $3,455,207,000 after buying an additional 824,750 shares during the period. Point72 Asset Management L.P. bought a new position in argenx during the fourth quarter valued at about $91,013,000. Allspring Global Investments Holdings LLC grew its position in argenx by 38,152.3% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 144,211 shares of the company's stock valued at $89,391,000 after buying an additional 143,834 shares during the period. Marshall Wace LLP grew its position in argenx by 184.7% during the fourth quarter. Marshall Wace LLP now owns 191,553 shares of the company's stock valued at $117,805,000 after buying an additional 124,271 shares during the period. Finally, Capital World Investors grew its position in argenx by 5.1% during the fourth quarter. Capital World Investors now owns 1,786,936 shares of the company's stock valued at $1,099,002,000 after buying an additional 86,687 shares during the period. Institutional investors own 60.32% of the company's stock.

argenx Stock Down 0.9%

Shares of ARGX stock traded down $4.95 during trading on Wednesday, hitting $574.82. The company had a trading volume of 59,207 shares, compared to its average volume of 360,209. argenx SE has a 52 week low of $359.36 and a 52 week high of $678.21. The stock's 50-day moving average is $588.46 and its two-hundred day moving average is $612.85. The stock has a market capitalization of $35.10 billion, a price-to-earnings ratio of -653.20 and a beta of 0.57.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported $2.58 EPS for the quarter, beating analysts' consensus estimates of $2.32 by $0.26. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $748.34 million. On average, research analysts predict that argenx SE will post 3.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on ARGX shares. Robert W. Baird upgraded shares of argenx from a "neutral" rating to an "outperform" rating and set a $680.00 price target for the company in a research report on Tuesday, May 13th. JMP Securities set a $699.00 price objective on shares of argenx in a report on Wednesday, May 14th. Citigroup reaffirmed a "buy" rating on shares of argenx in a report on Wednesday, May 21st. Oppenheimer upped their price objective on shares of argenx from $704.00 to $708.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Finally, Deutsche Bank Aktiengesellschaft raised shares of argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. One equities research analyst has rated the stock with a hold rating, twenty have assigned a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, argenx currently has a consensus rating of "Buy" and an average target price of $698.11.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.